homologous recombination repair deficiency
Gilead Sciences Acquires XinThera, Adds PARP1 Inhibitors to Oncology Pipeline
The acquisition will bring several oncology assets into Gilead's pipeline, including a PARP1 inhibitor that may enter clinical trials later this year.
FDA Expert Panel Recommends Lynparza, Zytiga Combo Only for BRCA1/2-Mutated Prostate Cancer Patients
The ODAC made the recommendation based on data from the PROpel trial, which demonstrated the greatest benefit in patients with BRCA1/2-mutated mCRPC.
Lynparza, Ceralasertib Combo Trial Provides Clues on Biomarkers of Response in Pediatric Cancer
In the tumor-agnostic study, pediatric patients with 11q loss and other alterations associated with replication stress benefited from the dual PARP-ATR inhibitor treatment.
NICE Reverses Course, Recommends Lynparza for BRCA1/2-Mutated Breast, Prostate Cancer
NICE previously said Merck and AstraZeneca's PARP inhibitor wasn't cost-effective but has reconsidered after striking a discounted commercial deal with the drugmakers.
Janssen Files for FDA Approval of PARP Inhibitor Combination in Frontline, BRCA-Positive mCRPC
The drugmaker is seeking approval for niraparib in a biomarker-defined patient population, unlike its competitors developing their PARP inhibitors for all comers.